Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of “Buy” by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned a consensus recommendation of “Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $158.6875.

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald boosted their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Mizuho initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $205.00 price objective for the company. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group lifted their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Finally, BTIG Research reissued a “buy” rating and issued a $192.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, January 29th.

Palvella Therapeutics Stock Performance

PVLA opened at $82.02 on Friday. Palvella Therapeutics has a one year low of $16.65 and a one year high of $114.69. The stock has a market cap of $971.12 million, a price-to-earnings ratio of -31.19 and a beta of -0.16. The stock’s 50 day moving average price is $93.65 and its 200-day moving average price is $75.22.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 12,906 shares of company stock worth $1,205,980. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PVLA. Millennium Management LLC bought a new stake in shares of Palvella Therapeutics in the 1st quarter valued at about $7,553,000. Goldman Sachs Group Inc. bought a new position in Palvella Therapeutics in the first quarter worth approximately $533,000. Geode Capital Management LLC lifted its holdings in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after buying an additional 79,787 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Palvella Therapeutics during the second quarter worth $37,000. Finally, JPMorgan Chase & Co. boosted its position in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.